25 Hydroxyvitamin D and vitamin E absorption in healthy children and children with chronic intrahepatic cholestasis.
Patients with chronic cholestasis have reduced 25-hydroxyvitamin D (25OHD) and vitamin E levels. We determined serum concentrations of 25OHD, 1,25-dihydroxyvitamin D [1,25(OH)2D] and vitamin E before and after oral administration of 10 micrograms/kg body weight 25-hydroxyvitamin D3 (25OHD3) and 100 IU/kg body weight vitamin E, respectively, in 4 patients with intrahepatic cholestasis and 6 healthy children. Vitamin E increased in all controls but in only one of the four patients. In contrast, oral 25OHD3 induced a normal rise in circulating 25OHD and 1,25(OH)2D. The low serum levels of 25OHD in the patients before the oral bolus may have been due to inadequate parenteral vitamin D administration and/or to the simultaneous phenobarbital treatment. The latter possibility is supported by the increase of serum 25OHD into the normal range after withdrawal of phenobarbital in one of the four patients. We conclude that vitamin E has to be supplemented parenterally or in water-soluble oral form. Further studies are necessary to clarify whether high-dose long-term oral 25OHD3 supplementation is sufficient to prevent vitamin D deficiency in patients with chronic cholestasis.
Issa
S
S
Kinderklinik der Universität, Bonn, Federal Republic of Germany.
Rotthauwe
H W
HW
Burmeister
W
W
D000293:Adolescent; D002112:Calcifediol / Q000378:metabolism*; D002648:Child; D002780:Cholestasis, Intrahepatic / Q000378:metabolism*; D002908:Chronic Disease; D005260:Female; D006801:Humans; D008297:Male; D014809:Vitamin D-Binding Protein / Q000502:physiology*; D014810:Vitamin E / Q000378:metabolism*
D014809:Vitamin D-Binding Protein; D014810:Vitamin E; D002112:Calcifediol